TABLE 1.

Demographic characteristics of subjects from whom HSV-2 UL23 sequences were obtained

Study	Location	HIV statusa	No. of subjects	Gender (%)	Age (mean yr)	ACV therapy (%)b	Duration of ACV (mean no. of moc)	Baseline CD4 (meand)
HPTN039	Peru	Neg	17e	Male (100)	28	100	9.1
HPTN039	San Francisco	Neg	1	Male (100)	35	100	8.2
HPTN039	South Africa	Neg	3	Female (100)	25	100	6.9
HPTN039	Zambia	Neg	6e	Female (100)	32	100	12.2
HPTN039	Zimbabwe	Neg	8e	Female (100)	30	100	11.7
PIPf	Kenya	Pos	3	Female (67)	35	67	20.4	550
				Male (33)
PIP	Uganda	Pos	2	Female (100)	30	100	6.0	484
Mwanza	Tanzania	Neg	3	Female (100)	23	33	12
Mwanza	Tanzania	Pos	21	Female (100)	27	67	17.1	352

^aAt the time of specimen collection. Pos, positive; Neg, negative.

^bPercentage of subjects assigned to receive ACV at the time of specimen collection.

^cAmong subjects assigned to receive ACV at the time of specimen collection. The totals in boldface exclude one Partners in Prevention subject, two Mwanza HIV-negative subjects, and seven Mwanza HIV-positive subjects who had not been started on acyclovir when the specimen was collected. These subjects were not included in calculations of means.

^dAmong subjects who were HIV infected at the time of specimen collection. CD4 counts were available for all Partners in Prevention subjects and 15 of the 21 HIV-positive subjects from the Mwanza study.

^eOne subject each from Zambia and Zimbabwe contributed two specimens each, and one subject from Peru contributed three specimens.

^fPIP, Partners in Prevention.